Abstract

BackgroundGut microbiota contributes to colorectal cancer (CRC) pathogenesis through microbes and their metabolites. The importance of microbiota-associated metabolites in colorectal carcinogenesis highlights the need to investigate the gut metabolome along the adenoma-carcinoma sequence to determine their mechanistic implications in the pathogenesis of CRC. To date, how and which microbes and metabolites interactively promote early events of CRC development are still largely unclear. We aim to determine gut microbiota-associated metabolites and their linkage to colorectal carcinogenesis.ResultsWe performed metabolomics and metagenomics profiling on fecal samples from 386 subjects including 118 CRC patients, 140 colorectal adenomas (CRA) patients and 128 healthy subjects as normal controls (NC). We identified differences in the gut metabolite profiles among NC, CRA and CRC groups by partial least squares-discriminant and principal component analyses. Among the altered metabolites, norvaline and myristic acid showed increasing trends from NC, through CRA, to CRC. CRC-associated metabolites were enriched in branched-chain amino acids, aromatic amino acids and aminoacyl-tRNA biosynthesis pathways. Moreover, metabolites marker signature (twenty metabolites) classified CRC from NC subjects with an area under the curve (AUC) of 0.80, and CRC from CRA with an AUC of 0.79. Integrative analyses of metabolomics and metagenomics profiles demonstrated that the relationships among CRC-associated metabolites and bacteria were altered across CRC stages; certain associations exhibited increasing or decreasing strengths while some were reversed from negative to positive or vice versa. Combinations of gut bacteria with the metabolite markers improved their diagnostic performances; CRC vs NC, AUC: 0.94; CRC vs CRA, AUC 0.92; and CRA vs NC, AUC: 0.86, indicating a potential for early diagnosis of colorectal neoplasia.ConclusionsThis study underscores potential early-driver metabolites in stages of colorectal tumorigenesis. The Integrated metabolite and microbiome analysis demonstrates that gut metabolites and their association with gut microbiota are perturbed along colorectal carcinogenesis. Fecal metabolites can be utilized, in addition to bacteria, for non-invasive diagnosis of colorectal neoplasia.3q4MPQh_hL9D7mm42bB_GTVideo

Highlights

  • Colorectal cancer (CRC) remains a significant global health burden, with the gut microbiota identified as a key player in its development

  • These include the enrichment of L-alanine, glycine, L-proline, L-aspartic acid, L-valine, L-leucine, L-serine, myristic acid, phenyl lactic acid, oxoglutaric acid, L-phenylalanine, L-alpha-aminobutyric acid, phenylacetic acid, palmitoleic acid, 3-aminoisobutanoic acid and norvaline

  • Butyric acid was depleted in colorectal cancer (CRC) patients compared with normal controls (NC) (Fig. 1C and Fig. S3A, Table S2)

Read more

Summary

Introduction

Colorectal cancer (CRC) remains a significant global health burden, with the gut microbiota identified as a key player in its development. Recent studies have shown that gut microbiota alteration can drive carcinogenesis by promoting hyperproliferation of colonic cells. During their colonization and propagation, gut bacteria produce an array of metabolites, which have both direct and indirect influence on host metabolism and immune responses. Gut microbiota and their metabolites were shown to induce epigenetic modifications of host cells [2], with the metabolites acting as crucial messengers in the crosstalk [3]. Gut microbiota contributes to colorectal cancer (CRC) pathogenesis through microbes and their metabolites. The importance of microbiota-associated metabolites in colorectal carcinogenesis highlights the need to investigate the gut metabolome along the adenoma-carcinoma sequence to determine their mechanistic implications in the pathogenesis of CRC. We aim to determine gut microbiota-associated metabolites and their linkage to colorectal carcinogenesis

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call